Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.

Via the factbox to the right, you can find a link to the decision and the letter which the Danish Medicines Agency has sent to companies holding a marketing authorisation for medicinal products comprised by the decision. All documents are in Danish.

For further information, please contact the Reimbursement Department at Send an email.

Danish Medicines Agency, 19 April 2010